Amgen Stock Price - AMGN

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 220.67 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.19 -0.09% 220.67 221.59 219.2055 221.06 220.86 00:00:02
Bid Price Ask Price Spread Spread % News
202.50 240.10 37.60 15.66% - 3
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
22,022 2,239,516 $ 220.30 $ 493,363,471 2,229,834 165.06 - 225.1752
Last Trade Time Type Quantity Stock Price Currency
18:26:24 15 $ 220.82 USD

Amgen Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 131.12B 594.18M $ 8.39B 12.60 16.90 591.26M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 5.28 2.39% 11/14/19 7.00 0.50%

more financials information »

Amgen News

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week220.24225.1752213.55220.102,205,6930.430.2%
1 Month203.57225.1752200.7827213.662,362,54417.108.4%
3 Months200.60225.1752188.78204.412,353,36920.0710.0%
6 Months168.50225.1752165.06192.592,655,76252.1730.96%
1 Year194.92225.1752165.06190.432,796,22325.7513.21%
3 Years147.05225.1752138.83180.663,035,40773.6250.06%
5 Years158.91225.1752130.08171.023,051,27061.7638.86%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191119 07:56:28